Literature DB >> 24976973

Unresectable stage III non-small cell lung cancer: is Tecemotide a new START for our patients?

Els Wauters1, Johan Vansteenkiste1.   

Abstract

Entities:  

Year:  2014        PMID： 24976973      PMCID： PMC4073368          DOI： 10.3978/j.issn.2072-1439.2014.05.16

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  14 in total

Review 1.  L-BLP25: a peptide vaccine strategy in non small cell lung cancer.

Authors:  Randeep Sangha; Charles Butts
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

2.  PL03.05 An intergroup randomized phase III comparison of standard-dose (60 Gy) vs high-dose (74 Gy) chemoradiotherapy (CRT) +/- cetuximab (cetux) for stage III non-small cell lung cancer (NSCLC): results on cetux from RTOG 0617.

Authors: 
Journal:  Clin Adv Hematol Oncol       Date:  2014-01

Review 3.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.

Authors:  Anne Aupérin; Cecile Le Péchoux; Estelle Rolland; Walter J Curran; Kiyoyuki Furuse; Pierre Fournel; Jose Belderbos; Gerald Clamon; Hakki Cuneyt Ulutin; Rebecca Paulus; Takeharu Yamanaka; Marie-Cecile Bozonnat; Apollonia Uitterhoeve; Xiaofei Wang; Lesley Stewart; Rodrigo Arriagada; Sarah Burdett; Jean-Pierre Pignon
Journal:  J Clin Oncol       Date:  2010-03-29       Impact factor: 44.544

4.  Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Authors:  Charles Butts; Mark A Socinski; Paul L Mitchell; Nick Thatcher; Libor Havel; Maciej Krzakowski; Sergiusz Nawrocki; Tudor-Eliade Ciuleanu; Lionel Bosquée; José Manuel Trigo; Alexander Spira; Lise Tremblay; Jan Nyman; Rodryg Ramlau; Gun Wickart-Johansson; Peter Ellis; Oleg Gladkov; José Rodrigues Pereira; Wilfried Ernst Erich Eberhardt; Christoph Helwig; Andreas Schröder; Frances A Shepherd
Journal:  Lancet Oncol       Date:  2013-12-09       Impact factor: 41.316

5.  Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.

Authors:  Charles Butts; Nevin Murray; Andrew Maksymiuk; Glenwood Goss; Ernie Marshall; Denis Soulières; Yvon Cormier; Peter Ellis; Allan Price; Ravinder Sawhney; Mary Davis; Janine Mansi; Colum Smith; Dimitrios Vergidis; Paul Ellis; Mary MacNeil; Martin Palmer
Journal:  J Clin Oncol       Date:  2005-09-20       Impact factor: 44.544

6.  A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.

Authors:  R O Dillman; S L Seagren; K J Propert; J Guerra; W L Eaton; M C Perry; R W Carey; E F Frei; M R Green
Journal:  N Engl J Med       Date:  1990-10-04       Impact factor: 91.245

7.  Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer.

Authors:  Hak Choy; Lee S Schwartzberg; Shaker R Dakhil; Edward B Garon; David E Gerber; Janak K Choksi; Ramaswamy Govindan; Guangbin Peng; Andrew Koustenis; Joseph Treat; Coleman Obasaju
Journal:  J Thorac Oncol       Date:  2013-10       Impact factor: 15.609

8.  Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

Authors:  Karen Kelly; Kari Chansky; Laurie E Gaspar; Kathy S Albain; James Jett; Yee C Ung; Derick H M Lau; John J Crowley; David R Gandara
Journal:  J Clin Oncol       Date:  2008-03-31       Impact factor: 44.544

9.  INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer.

Authors:  Yi-Long Wu; Keunchil Park; Ross A Soo; Yan Sun; Karin Tyroller; David Wages; Guy Ely; James Chih-Hsin Yang; Tony Mok
Journal:  BMC Cancer       Date:  2011-10-07       Impact factor: 4.430

10.  Increased expression after X-irradiation of MUC1 in cultured human colon carcinoma HT-29 cells.

Authors:  Y Kang; K Hirano; N Suzuki; A Enomoto; A Morita; T Irimura; K Sakai
Journal:  Jpn J Cancer Res       Date:  2000-03
View more
  1 in total

1.  Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer.

Authors:  Priyanka Bobbili; Kellie Ryan; Maral DerSarkissian; Akanksha Dua; Christopher Yee; Mei Sheng Duh; Jorge E Gomez
Journal:  PLoS One       Date:  2020-03-18       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.